BHCM
BMY icon

Brevan Howard Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Brevan Howard Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.45M Sell
163,962
-6,549
-4% -$376K 0.07% 187
2026
Q1 		$10.3M Sell
170,511
-105,722
-38% -$6.16M 0.09% 125
2025
Q4 		$14.9M Buy
276,233
+203,575
+280% +$9.79M 0.16% 81
2025
Q3 		$3.28M Sell
72,658
-90,594
-55% -$4.23M 0.01% 378
2025
Q2 		$7.56M Buy
+163,252
New +$8.01M 0.04% 245
2025
Q1 		– Sell
-142,886
Closed -$8.08M – 1176
2024
Q4 		$8.08M Buy
142,886
+106,230
+290% +$5.94M 0.05% 86
2024
Q3 		$1.9M Buy
36,656
+30,129
+462% +$1.41M 0.01% 293
2024
Q2 		$271K Buy
+6,527
New +$292K ﹤0.01% 813
2024
Q1 		– Sell
-18,098
Closed -$929K – 1024
2023
Q4 		$929K Buy
18,098
+1,245
+7% +$65.4K 0.01% 259
2023
Q3 		$978K Buy
+16,853
New +$1.03M 0.01% 91

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brevan Howard Capital Management's BMY Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 3.8% in Q2 2026, selling an estimated $376K and leaving 163,962 shares worth $9.45M. The position accounts for 0.07% of the portfolio, ranked #187.

Brevan Howard Capital Management first reported a position in BMY in Q3 2023 and has held it in 10 quarters since. The position peaked at $14.9M in Q4 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Brevan Howard Capital Management held 163,962 shares of Bristol-Myers Squibb worth $9.45M as of Q2 2026.
  • Brevan Howard Capital Management sold 6,549 Bristol-Myers Squibb shares in Q2 2026, an estimated $376K.
  • Bristol-Myers Squibb made up 0.07% of Brevan Howard Capital Management's portfolio in Q2 2026, its #187 holding.
  • Brevan Howard Capital Management first reported a position in Bristol-Myers Squibb in Q3 2023 and has held it in 10 quarters since.
  • Brevan Howard Capital Management's Bristol-Myers Squibb position peaked at $14.9M in Q4 2025.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.